A federal outside panel voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is not final. The FDA has given no word on whether it will take up the recommendation. The move came after weeks of community hearings. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could reshape how the agency handles a part of the wellness market that is scaling quickly. Watchers are waiting to see if the regulator moves in step. A representative for the agency offered no set date for a reaction. Critics argue the change would broaden access to compounds people say help them. Health groups warn that looser rules could invite misuse across a quickly growing market. The vote only sets up a possible shift, and the final say rests with the federal agency.